CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
FGFR1 is a receptor tyrosine kinase that drives multiple intracellular signaling pathways involved in tumor cell proliferation, survival and progression. Because these pathways are frequently ...
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
Laboratory studies suggest cinnamon’s bioactive compounds can alter key cancer-related signaling pathways, but researchers caution that human trials are essential before any preventive or therapeutic ...
Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies. A new study ...
While metabolomics is the large-scale comprehensive profiling of metabolites and other small molecules in the context of ...
Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study in metastatic breast cancer ...
Z-endoxifen has demonstrated efficacy in phase 1 and 2 trials, improving progression-free survival and tumor response in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback